{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:40:52Z","timestamp":1793878852602,"version":"4.7.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2022,6,10]]},"DOI":"10.1038\/s41388-022-02340-8","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T06:05:04Z","timestamp":1651903504000},"page":"3328-3340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic"],"prefix":"10.1038","volume":"41","author":[{"given":"Dongxu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-7890","authenticated-orcid":false,"given":"Xufen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8075-3883","authenticated-orcid":false,"given":"Jithesh","family":"Kottur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Byrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick D.","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Mackintosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel K.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Tackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-9940","authenticated-orcid":false,"given":"Gang Greg","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"key":"2340_CR1","doi-asserted-by":"publisher","first-page":"37740","DOI":"10.18632\/oncotarget.9312","volume":"7","author":"Z Ge","year":"2016","unstructured":"Ge Z, Song EJ, Kawasawa YI, Li J, Dovat S, Song C. WDR5 high expression and its effect on tumorigenesis in leukemia. Oncotarget. 2016;7:37740\u201354.","journal-title":"Oncotarget"},{"key":"2340_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","volume":"16","author":"A Carugo","year":"2016","unstructured":"Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, et al. In vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer. Cell Rep. 2016;16:133\u201347.","journal-title":"Cell Rep."},{"key":"2340_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1158\/0008-5472.CAN-15-0423","volume":"75","author":"Y Sun","year":"2015","unstructured":"Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, et al. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Cancer Res. 2015;75:5143\u201354.","journal-title":"Cancer Res"},{"key":"2340_CR4","doi-asserted-by":"publisher","first-page":"12902","DOI":"10.1073\/pnas.231473398","volume":"98","author":"T Miller","year":"2001","unstructured":"Miller T, Krogan NJ, Dover J, Erdjument-Bromage H, Tempst P, Johnston M, et al. COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc Natl Acad Sci USA. 2001;98:12902\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2340_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nsmb0709-678","volume":"16","author":"RC Trievel","year":"2009","unstructured":"Trievel RC, Shilatifard A. WDR5, a complexed protein. Nat Struct Mol Biol. 2009;16:678\u201380.","journal-title":"Nat Struct Mol Biol"},{"key":"2340_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015;15:334\u201346.","journal-title":"Nat Rev Cancer"},{"key":"2340_CR7","doi-asserted-by":"publisher","first-page":"32158","DOI":"10.1074\/jbc.C800164200","volume":"283","author":"A Patel","year":"2008","unstructured":"Patel A, Dharmarajan V, Cosgrove MS. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide. J Biol Chem. 2008;283:32158\u201361.","journal-title":"J Biol Chem"},{"key":"2340_CR8","doi-asserted-by":"publisher","first-page":"32162","DOI":"10.1074\/jbc.M806317200","volume":"283","author":"A Patel","year":"2008","unstructured":"Patel A, Vought VE, Dharmarajan V, Cosgrove MS. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex. J Biol Chem. 2008;283:32162\u201375.","journal-title":"J Biol Chem"},{"key":"2340_CR9","doi-asserted-by":"publisher","first-page":"27275","DOI":"10.1074\/jbc.M112.364125","volume":"287","author":"V Dharmarajan","year":"2012","unstructured":"Dharmarajan V, Lee JH, Patel A, Skalnik DG, Cosgrove MS. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases. J Biol Chem. 2012;287:27275\u201389.","journal-title":"J Biol Chem"},{"key":"2340_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molcel.2015.02.028","volume":"58","author":"LR Thomas","year":"2015","unstructured":"Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58:440\u201352.","journal-title":"Mol Cell"},{"key":"2340_CR11","doi-asserted-by":"crossref","unstructured":"Guarnaccia AD, Tansey WP. Moonlighting with WDR5: a cellular multitasker. J Clin Med. 2018; 7.","DOI":"10.3390\/jcm7020021"},{"key":"2340_CR12","doi-asserted-by":"publisher","first-page":"22357","DOI":"10.1074\/jbc.M116.752626","volume":"291","author":"NL Alicea-Velazquez","year":"2016","unstructured":"Alicea-Velazquez NL, Shinsky SA, Loh DM, Lee JH, Skalnik DG, Cosgrove MS. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)\/SET1 family proteins specifically inhibits MLL1 and SETd1A methyltransferase complexes. J Biol Chem. 2016;291:22357\u201372.","journal-title":"J Biol Chem"},{"key":"2340_CR13","doi-asserted-by":"publisher","first-page":"32967","DOI":"10.1074\/jbc.M110.159921","volume":"285","author":"Z Odho","year":"2010","unstructured":"Odho Z, Southall SM, Wilson JR. Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1. J Biol Chem. 2010;285:32967\u201376.","journal-title":"J Biol Chem"},{"key":"2340_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1042\/BJ20121280","volume":"449","author":"G Senisterra","year":"2013","unstructured":"Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrovski L, et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2013;449:151\u20139.","journal-title":"Biochem J"},{"key":"2340_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1021\/ml300467n","volume":"4","author":"Y Bolshan","year":"2013","unstructured":"Bolshan Y, Getlik M, Kuznetsova E, Wasney GA, Hajian T, Poda G, et al. Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. ACS Med Chem Lett. 2013;4:353\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"2340_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1021\/ja306028q","volume":"135","author":"H Karatas","year":"2013","unstructured":"Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1\/WDR5 protein-protein interaction. J Am Chem Soc. 2013;135:669\u201382.","journal-title":"J Am Chem Soc"},{"key":"2340_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.molcel.2013.12.001","volume":"53","author":"F Cao","year":"2014","unstructured":"Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 2014;53:247\u201361.","journal-title":"Mol Cell"},{"key":"2340_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nchembio.1859","volume":"11","author":"F Grebien","year":"2015","unstructured":"Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, et al. Pharmacological targeting of the Wdr5-MLL interaction in C\/EBPalpha N-terminal leukemia. Nat Chem Biol. 2015;11:571\u20138.","journal-title":"Nat Chem Biol"},{"key":"2340_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525:206\u201311.","journal-title":"Nature"},{"key":"2340_CR20","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1021\/acs.jmedchem.5b01630","volume":"59","author":"M Getlik","year":"2016","unstructured":"Getlik M, Smil D, Zepeda-Velazquez C, Bolshan Y, Poda G, Wu H, et al. Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1). J Med. Chem. 2016;59:2478\u201396.","journal-title":"J Med. Chem"},{"key":"2340_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejmech.2016.08.036","volume":"124","author":"DD Li","year":"2016","unstructured":"Li DD, Chen WL, Wang ZH, Xie YY, Xu XL, Jiang ZY, et al. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. Eur J Med Chem. 2016;124:480\u20139.","journal-title":"Eur J Med Chem"},{"key":"2340_CR22","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1021\/acs.jmedchem.6b01796","volume":"60","author":"H Karatas","year":"2017","unstructured":"Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y, et al. Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)-mixed lineage leukemia (MLL) protein-protein interaction. J medicinal Chem. 2017;60:4818\u201339.","journal-title":"J medicinal Chem"},{"key":"2340_CR23","doi-asserted-by":"crossref","unstructured":"Wang F, Jeon KO, Salovich JM, Macdonald JD, Alvarado J, Gogliotti RD. et al. Discovery of potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-site inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 2018;61:5623\u201342..","DOI":"10.1021\/acs.jmedchem.8b00375"},{"key":"2340_CR24","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.celrep.2019.02.047","volume":"26","author":"ER Aho","year":"2019","unstructured":"Aho ER, Wang J, Gogliotti RD, Howard GC, Phan J, Acharya P, et al. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Rep. 2019;26:2916\u201328. e2913","journal-title":"Cell Rep."},{"key":"2340_CR25","doi-asserted-by":"publisher","first-page":"11232","DOI":"10.1021\/acs.jmedchem.9b01411","volume":"62","author":"JD Macdonald","year":"2019","unstructured":"Macdonald JD, Chacon Simon S, Han C, Wang F, Shaw JG, Howes JE, et al. Discovery and optimization of salicylic acid-derived sulfonamide inhibitors of the WD repeat-containing protein 5-MYC protein-protein interaction. J Med Chem. 2019;62:11232\u201359.","journal-title":"J Med Chem"},{"key":"2340_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acs.jmedchem.9b01608","volume":"63","author":"J Tian","year":"2020","unstructured":"Tian J, Teuscher KB, Aho ER, Alvarado JR, Mills JJ, Meyers KM, et al. Discovery and structure-based optimization of potent and selective WD repeat domain 5 (WDR5) inhibitors containing a dihydroisoquinolinone bicyclic core. J Med Chem. 2020;63:656\u201375.","journal-title":"J Med Chem"},{"key":"2340_CR27","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1021\/acs.jmedchem.0c00224","volume":"63","author":"S Chacon Simon","year":"2020","unstructured":"Chacon Simon S, Wang F, Thomas LR, Phan J, Zhao B, Olejniczak ET, et al. Discovery of WD repeat-containing protein 5 (WDR5)-MYC inhibitors using fragment-based methods and structure-based design. J Med Chem. 2020;63:4315\u201333.","journal-title":"J Med Chem"},{"key":"2340_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16:101\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"2340_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:949\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"2340_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale B, Cheng M, Park KS, Kaniskan HU, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638\u201354.","journal-title":"Nat Rev Cancer"},{"key":"2340_CR31","doi-asserted-by":"publisher","first-page":"eabj1578","DOI":"10.1126\/scitranslmed.abj1578","volume":"13","author":"X Yu","year":"2021","unstructured":"Yu X, Li D, Kottur J, Shen Y, Kim HS, Park KS, et al. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Sci Transl Med. 2021;13:eabj1578.","journal-title":"Sci Transl Med"},{"key":"2340_CR32","doi-asserted-by":"publisher","first-page":"10682","DOI":"10.1021\/acs.jmedchem.1c00146","volume":"64","author":"A Dolle","year":"2021","unstructured":"Dolle A, Adhikari B, Kramer A, Weckesser J, Berner N, Berger LM, et al. Design, synthesis, and evaluation of WD-repeat-containing protein 5 (WDR5) degraders. J Med Chem. 2021;64:10682\u2013710.","journal-title":"J Med Chem"},{"key":"2340_CR33","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.M117.816868","volume":"293","author":"AA Akuffo","year":"2018","unstructured":"Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem. 2018;293:6187\u2013200.","journal-title":"J Biol Chem"},{"key":"2340_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19202-7","volume":"8","author":"T Mori","year":"2018","unstructured":"Mori T, Ito T, Liu S, Ando H, Sakamoto S, Yamaguchi Y, et al. Structural basis of thalidomide enantiomer binding to cereblon. Sci Rep. 2018;8:1294.","journal-title":"Sci Rep."},{"key":"2340_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305\u20139.","journal-title":"Science"},{"key":"2340_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183\u20138.","journal-title":"Nature"},{"key":"2340_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535:252\u20137.","journal-title":"Nature"},{"key":"2340_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/acschembio.7b00969","volume":"13","author":"M Ishoey","year":"2018","unstructured":"Ishoey M, Chorn S, Singh N, Jaeger MG, Brand M, Paulk J, et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem Biol. 2018;13:553\u201360.","journal-title":"ACS Chem Biol"},{"key":"2340_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat Commun. 2017;8:15398.","journal-title":"Nat Commun"},{"key":"2340_CR40","doi-asserted-by":"publisher","first-page":"788440","DOI":"10.3389\/fmolb.2021.788440","volume":"8","author":"R Xia","year":"2021","unstructured":"Xia R, Cheng Y, Han X, Wei Y, Wei X. Ikaros proteins in tumor: current perspectives and new developments. Front Mol Biosci. 2021;8:788440.","journal-title":"Front Mol Biosci"},{"key":"2340_CR41","doi-asserted-by":"crossref","unstructured":"Park I, Phan TM, Fang J. Novel molecular mechanism of lenalidomide in myeloid malignancies independent of deletion of chromosome 5q. Cancers (Basel) 2021; 13.","DOI":"10.3390\/cancers13205084"},{"key":"2340_CR42","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2005.04.031","volume":"121","author":"Y Dou","year":"2005","unstructured":"Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell. 2005;121:873\u201385.","journal-title":"Cell"},{"key":"2340_CR43","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nsmb1131","volume":"13","author":"MM Steward","year":"2006","unstructured":"Steward MM, Lee JS, O\u2019Donovan A, Wyatt M, Bernstein BE, Shilatifard A. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol. 2006;13:852\u20134.","journal-title":"Nat Struct Mol Biol"},{"key":"2340_CR44","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1074\/jbc.M110.174524","volume":"286","author":"A Patel","year":"2011","unstructured":"Patel A, Vought VE, Dharmarajan V, Cosgrove MS. A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem. 2011;286:3359\u201369.","journal-title":"J Biol Chem"},{"key":"2340_CR45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41568-021-00357-x","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21:413\u201330.","journal-title":"Nat Rev Cancer"},{"key":"2340_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc2876","volume":"10","author":"P Chi","year":"2010","unstructured":"Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10:457\u201369.","journal-title":"Nat Rev Cancer"},{"key":"2340_CR47","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aam7304","volume":"355","author":"MA Dawson","year":"2017","unstructured":"Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355:1147\u201352.","journal-title":"Science"},{"key":"2340_CR48","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1093\/emboj\/20.24.7137","volume":"20","author":"A Roguev","year":"2001","unstructured":"Roguev A, Schaft D, Shevchenko A, Pijnappel WW, Wilm M, Aasland R, et al. The Saccharomyces cerevisiae Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4. EMBO J. 2001;20:7137\u201348.","journal-title":"EMBO J"},{"key":"2340_CR49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","volume":"133","author":"D Dobrovolsky","year":"2019","unstructured":"Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019;133:952\u201361.","journal-title":"Blood"},{"key":"2340_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nchembio.1471","volume":"10","author":"P Ciceri","year":"2014","unstructured":"Ciceri P, Muller S, O\u2019Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol. 2014;10:305\u201312.","journal-title":"Nat Chem Biol"},{"key":"2340_CR51","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","volume":"11","author":"A Romanelli","year":"2020","unstructured":"Romanelli A, Stazi G, Fioravanti R, Zwergel C, Di Bello E, Pomella S, et al. Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells. ACS Med Chem Lett. 2020;11:977\u201383.","journal-title":"ACS Med Chem Lett"},{"key":"2340_CR52","unstructured":"Jin J, Wang G, Liu J, Yu X, Li D. WD40 REPEAT DOMAIN PROTEIN 5 (WDR5) DEGRADATION\/DISRUPTION COMPOUNDS AND METHODS OF USE. WO2019246570; 2019."},{"key":"2340_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13:514\u201321.","journal-title":"Nat Chem Biol"},{"key":"2340_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21357-3","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Galbo PM Jr., Gong W, Storey AJ, Tsai YH, Yu X, et al. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4\/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Nat Commun. 2021;12:1045.","journal-title":"Nat Commun"},{"key":"2340_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccell.2016.05.008","volume":"30","author":"R Lu","year":"2016","unstructured":"Lu R, Wang P, Parton T, Zhou Y, Chrysovergis K, Rockowitz S, et al. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell. 2016;30:92\u2013107.","journal-title":"Cancer Cell"},{"key":"2340_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molcel.2018.08.029","volume":"72","author":"L Cai","year":"2018","unstructured":"Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer. Mol cell. 2018;72:341\u201354. e346","journal-title":"Mol cell"},{"key":"2340_CR57","doi-asserted-by":"publisher","first-page":"e0166438","DOI":"10.1371\/journal.pone.0166438","volume":"11","author":"B Egan","year":"2016","unstructured":"Egan B, Yuan CC, Craske ML, Labhart P, Guler GD, Arnott D, et al. An alternative approach to chip-seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 Inhibition. PLoS ONE. 2016;11:e0166438.","journal-title":"PLoS ONE"},{"key":"2340_CR58","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41586-021-03662-5","volume":"595","author":"JH Ahn","year":"2021","unstructured":"Ahn JH, Davis ES, Daugird TA, Zhao S, Quiroga IY, Uryu H, et al. Phase separation drives aberrant chromatin looping and cancer development. Nature. 2021;595:591\u20135.","journal-title":"Nature"},{"key":"2340_CR59","doi-asserted-by":"publisher","first-page":"16008","DOI":"10.1038\/celldisc.2016.8","volume":"2","author":"J Xu","year":"2016","unstructured":"Xu J, Li L, Xiong J, DenDekker A, Ye A, Karatas H, et al. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discov. 2016;2:16008.","journal-title":"Cell Discov"},{"key":"2340_CR60","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41588-020-00729-3","volume":"52","author":"H Fan","year":"2020","unstructured":"Fan H, Lu J, Guo Y, Li D, Zhang ZM, Tsai YH, et al. BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. Nat Genet. 2020;52:1384\u201396.","journal-title":"Nat Genet"},{"key":"2340_CR61","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood.2019000578","volume":"134","author":"Z Ren","year":"2019","unstructured":"Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019;134:1176\u201389.","journal-title":"Blood"},{"key":"2340_CR62","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature12210","volume":"498","author":"W Li","year":"2013","unstructured":"Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature. 2013;498:516\u201320.","journal-title":"Nature"},{"key":"2340_CR63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346\u201357.","journal-title":"Blood"},{"key":"2340_CR64","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koster J, DeSouza TA, et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016;29:574\u201386.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02340-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02340-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T02:05:16Z","timestamp":1654826716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02340-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":64,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,6,10]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02340-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,7]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJ, GW, JL, XY, and DL are inventors of a patent application filed by the Icahn School of Medicine at Mount Sinai and University of North Carolina at Chapel Hill. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. JJ is a cofounder, scientific advisory board member and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc. and Accent Therapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}